Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q4 2016 · 10-K
Revenue$8.51M$8.51M+43.4% vs Q4 2015 Net Income-$26.23M-$26.23MN/M vs Q4 2015 EPS Diluted-$0.36-$0.36N/M vs Q4 2015 Operating Income-$22,363,296N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,969,174N/M Margins · derivedOperating margin-262.7%−17.9 pt vs Q4 2015
Net margin-308.1%−5.7 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 15, 2017 · 74 d after period end